|
HLA-C alleles in controls and in Alzheimer's disease |
|||||||
| Allele |
Homozygotes/heterozygotes/negatives (n) |
Allelic frequency (%) |
Unadjusted allelic odds ratio of AD (95% CI, p†) |
Hardy-Weinberg equilibrium (p†) |
|||
|
|
|||||||
| Controls |
AD |
Controls |
AD |
Controls |
AD |
||
|
|
|||||||
| HLA-Cw1 |
0/9/190 |
1/14/180 |
2.3 |
4.1 |
1.85 (0.8–4.2, 0.2) |
0.7 |
0.2 |
| HLA-Cw2 |
0/15/184 |
0/16/179 |
3.8 |
4.1 |
1.1 (0.5–2.2, 0.9) |
0.6 |
0.55 |
| HLA-Cw4 |
1/36/162 |
1/34/160 |
9.5 |
9.2 |
1.0 (0.6–1.6, 0.9) |
0.5 |
0.6 |
| HLA-Cw5 |
1/36/162 |
1/40/154 |
9.5 |
10.8 |
1.1 (0.7–1.8, 0.6) |
0.5 |
0.35 |
| HLA-Cw6 |
4/31/164 |
2/31/162 |
9.8 |
9.0 |
0.9 (0.6–1.5, 0.7) |
0.09 |
0.7 |
| HLA-Cw*0701 |
6/62/131 |
7/56/132 |
18.6 |
17.9 |
1.0 (0.7–1.4, 0.85) |
0.7 |
0.7 |
| HLA-Cw*0702 |
1/46/152 |
9/58/128 |
12.1 |
19.5 |
1.8 (1.2–2.6, 0.0045) |
0.2 |
0.5 |
| HLA-Cw*0704 |
0/8/191 |
0/3/192 |
2.0 |
0.8 |
0.4 (0.1–1.4, 0.2) |
0.8 |
0.9 |
| HLA-Cw8 |
0/17/182 |
1/11/183 |
4.3 |
3.3 |
0.8 (0.4–1.6, 0.6) |
0.5 |
0.08 |
| HLA-Cw9 |
0/29/170 |
0/25/170 |
7.3 |
6.4 |
0.9 (0.5–1.5, 0.7) |
0.3 |
0.3 |
| HLA-Cw10 |
1/37/161 |
2/24/169 |
9.8 |
7.2 |
0.7 (0.4–1.2, 0.2) |
0.5 |
0.3 |
| HLA-Cw12 |
1/11/187 |
0/8/187 |
3.3 |
2.1 |
0.6 (0.25–1.5, 0.4) |
0.08 |
0.8 |
| HLA-Cw15 |
0/13/186 |
0/2/193 |
3.3 |
0.5 |
0.15 (0.03–0.7, 0.007) |
0.6 |
0.9 |
| HLA-Cw16 |
0/13/186 |
1/13/181 |
3.3 |
3.8 |
1.2 (0.6–2.5, 0.7) |
0.6 |
0.2 |
|
AD = Alzheimer's disease, CI = confidence interval †uncorrected | |||||||
Lehmann et al. Journal of Neuroinflammation 2006 3:33 doi:10.1186/1742-2094-3-33 |
|||||||